Conference Coverage
Conference Coverage
Genetic screening for CLL premature, speaker says
Photo courtesy of the National Institute of General Medical Science NEW YORK—Research has shown that family history is a strong risk factor for...
Conference Coverage
CAR T-cell therapy eyed for CLL patients with residual disease
Key clinical point: CAR T-cell therapy may be an option for chronic lymphocytic leukemia patients with residual disease after upfront therapy....
Conference Coverage
Three-drug regimen boosts progression-free survival in patients with relapsed CLL and adverse prognostic features
Key clinical point: Progression-free survival was improved for poor prognosis patients with relapsed chronic lymphocytic leukemia when idelalisib...
Conference Coverage
Maintenance rituximab extends progression-free but not overall survival in CLL
Key clinical point: Progression-free survival, but not overall survival, was improved after 2 years of maintenance immunotherapy with rituximab....
Conference Coverage
Dr. Matt Kalaycio’s top 10 hematologic oncology abstracts for ASCO 2016
Conference Coverage
Venetoclax achieves responses in CLL refractory to ibrutinib, idelalisib
Key clinical point: Venetoclax can achieve responses in patients who are refractory to ibrutinib. Major finding: The overall response rate was 61...
Conference Coverage
Treatment can produce durable responses in NHL
2016 AACR Annual Meeting © AACR/Todd Buchanan NEW ORLEANS—Administering an antibody-radionuclide conjugate after B-cell depletion with rituximab...
Conference Coverage
Drug shows early promise for low-grade lymphoma
follicular lymphoma NEW ORLEANS—The TLR9 agonist SD-101 has produced encouraging early results in patients with low-grade B-cell lymphoma,...
Conference Coverage
Venetoclax gets 79% overall response rate in high-risk CLL
Conference Coverage
EZH2 inhibitor can produce durable responses
ORLANDO, FL—Updated results of a phase 1 study suggest the EZH2 inhibitor tazemetostat (EPZ-6438) can produce durable responses in patients with...